一种在肺腺癌中发现的新型EML4-ALK与BIRC6-ALK双融合变体对阿来替尼敏感。 - Suppr

A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.

作者信息

Zhong Jiang-Ming, Zhang Gui-Feng, Lin Li, Li De-Yu, Liu Zhen-Hua

机构信息

Department of Medical Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, PR China.

出版信息

Lung Cancer. 2020 Jul;145:211-212. doi: 10.1016/j.lungcan.2020.04.030. Epub 2020 May 4.

DOI:10.1016/j.lungcan.2020.04.030

PMID:32409002

Abstract

摘要

相似文献

A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.一种在肺腺癌中发现的新型EML4-ALK与BIRC6-ALK双融合变体对阿来替尼敏感。

Lung Cancer. 2020 Jul;145:211-212. doi: 10.1016/j.lungcan.2020.04.030. Epub 2020 May 4.

Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.新型 EML4-ALK 变异肺腺癌患者的艾乐替尼治疗反应。

Thorac Cancer. 2018 Oct;9(10):1327-1332. doi: 10.1111/1759-7714.12834. Epub 2018 Aug 21.

A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.ALK 融合基因罕见变异型 EML4-ALK 外显子 6 与 ALK 外显子 18 融合：阿来替尼治疗肺腺癌 1 例报告

J Natl Compr Canc Netw. 2021 Nov 11;20(1):2-6. doi: 10.6004/jnccn.2021.7077.

Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.新型 NBEA-ALK、EML4-ALK 双融合在肺腺癌患者中的共存及阿来替尼治疗反应：一例报告。

Lung Cancer. 2021 Dec;162:86-89. doi: 10.1016/j.lungcan.2021.10.015. Epub 2021 Nov 5.

Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.肺腺癌中 EML4-ALK 外显子 19 融合变体的鉴定及艾乐替尼耐药。

Lung Cancer. 2021 Oct;160:32-35. doi: 10.1016/j.lungcan.2021.07.020. Epub 2021 Aug 6.

EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.右小腿骨骼肌转移的EML4-ALK阳性肺腺癌，在对阿来替尼治疗耐药后可用劳拉替尼治疗。

BMJ Case Rep. 2021 Apr 27;14(4):e240295. doi: 10.1136/bcr-2020-240295.

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.EML4-ALK融合作为奥希替尼的耐药机制及其通过奥希替尼和阿来替尼成功治疗：病例报告及文献综述

Clin Lung Cancer. 2020 Nov;21(6):e597-e600. doi: 10.1016/j.cllc.2020.05.016. Epub 2020 May 23.

ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib.对阿来替尼耐药且伴有菜花状牙龈转移的ALK重排肺腺癌对布加替尼有反应。

Thorac Cancer. 2022 Apr;13(7):1095-1097. doi: 10.1111/1759-7714.14347. Epub 2022 Feb 11.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.更新的疗效和安全性数据以及 EML4-ALK 融合变体对全球 III 期 ALEX 研究中未经治疗的 ALK 阳性晚期非小细胞肺癌中阿来替尼疗效的影响。

J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20.

Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.新型 SSFA2-ALK 融合的肺腺癌患者对阿来替尼的显著反应。

Invest New Drugs. 2022 Oct;40(5):1160-1163. doi: 10.1007/s10637-022-01260-4. Epub 2022 May 24.

引用本文的文献

Coexistence of a novel , double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review.一名肺低分化腺癌患者中新型双融合的共存及对阿来替尼的反应：病例报告与文献综述

Front Oncol. 2024 Dec 13;14:1453259. doi: 10.3389/fonc.2024.1453259. eCollection 2024.

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.PLEKHA7-ALK和INPP5D-ALK的伴随双融合揭示了肺腺癌对阿来替尼的良好敏感性：一例报告及文献综述

Discov Oncol. 2024 Feb 20;15(1):43. doi: 10.1007/s12672-024-00899-0.

Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase () rearrangements and co-existing alterations-a retrospective cohort study.阿来替尼在不同间变性淋巴瘤激酶（ALK）重排及共存改变的肺腺癌患者中的疗效——一项回顾性队列研究

Transl Lung Cancer Res. 2023 Dec 26;12(12):2505-2519. doi: 10.21037/tlcr-23-658. Epub 2023 Nov 22.

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.两例病例报告：EML4-ALK重排的大细胞神经内分泌癌及文献综述

Front Oncol. 2023 Nov 1;13:1227980. doi: 10.3389/fonc.2023.1227980. eCollection 2023.

[Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma  with COX7A2L-ALK Fusion: A Case Report and Literature Review].[塞瑞替尼作为伴有COX7A2L-ALK融合的晚期肺腺癌一线治疗：一例报告及文献综述]

Zhongguo Fei Ai Za Zhi. 2023 Apr 20;26(4):319-324. doi: 10.3779/j.issn.1009-3419.2023.102.15.

Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.一例晚期肺腺癌患者在阿来替尼耐药后出现新型SETD2-ALK、EML4-ALK双融合并对免疫治疗联合化疗有反应：病例报告

Discov Oncol. 2023 Apr 13;14(1):44. doi: 10.1007/s12672-023-00654-x.

Case Report: Identification of Two Rare Fusions, and , That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib.病例报告：在一名肺腺癌患者中鉴定出两种罕见融合基因和及其对阿来替尼的反应。

Front Oncol. 2021 Aug 13;11:722843. doi: 10.3389/fonc.2021.722843. eCollection 2021.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献